This health department is offering a grant aimed at supporting research, development, and introduction of microbicides. The funding opportunity, detailed in the attached document, is open until July 11, 2014. Eligible applicants can apply to contribute to advancing microbicide research and development to combat various health challenges.
Opportunity ID: 256908
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | APS-OAA-14-000076 |
| Funding Opportunity Title: | Microbicide Research, Development, and Introduction, Round 3 |
| Opportunity Category: | Other |
| Opportunity Category Explanation: | CategoryExplanation |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Other (see text field entitled “Explanation of Other Category of Funding Activity” for clarification) |
| Category Explanation: | The CAPRISA 004 clinical trial of 1% tenofovir gel, conducted by South African investigators and jointly supported by USAID and the Government of South Africa, was the first demonstration that a vaginal microbicide could significantly reduce the risk of HIV infection. This proof of concept, announced in July 2010, focused attention on the need to confirm the safety and effectiveness of this product, obtain regulatory approval from the relevant national authorities, and prepare for introduction of this new HIV prevention technology designed to help meet the needs of women in developing countries. Simultaneously, other promising microbicide leads are moving forward in the product development pipeline as well. Although research and development (R&D) for improved and alternative microbicide products will continue to be of interest, a new and broader range of activities is now needed to move the USAID program forward toward microbicide introduction.
This APS is intended to support the creative research and other innovative activities that are now essential to advance potential microbicides toward regulatory approval and then to successfully introduce them into delivery programs. Attaining these objectives will fill a critical gap in the options women and girls currently have to protect themselves from HIV infection. |
| Expected Number of Awards: | – |
| Assistance Listings: | 98.001 — USAID Foreign Assistance for Programs Overseas |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 06, 2014 |
| Last Updated Date: | Jul 03, 2014 |
| Original Closing Date for Applications: | Jul 09, 2014 |
| Current Closing Date for Applications: | Jul 11, 2014 |
| Archive Date: | Aug 08, 2014 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $4,000,000 |
| Award Floor: | $1,000,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility requirements included in attached document. |
Additional Information
| Agency Name: | Agency for International Development |
| Description: | Description of funding opportunity included in attached document. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Petrina Williams
Contract Specialist Phone 202-567-5368 Email:pwilliams@usaid.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The closing date of this APS has been extended from July 9, 2014 until 2:00 PM on July 11, 2014. | Jul 03, 2014 | |
| Jul 03, 2014 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | APS-OAA-14-000076 |
| Funding Opportunity Title: | Microbicide Research, Development, and Introduction, Round 3 |
| Opportunity Category: | Other |
| Opportunity Category Explanation: | CategoryExplanation |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Other (see text field entitled “Explanation of Other Category of Funding Activity” for clarification) |
| Category Explanation: | The CAPRISA 004 clinical trial of 1% tenofovir gel, conducted by South African investigators and jointly supported by USAID and the Government of South Africa, was the first demonstration that a vaginal microbicide could significantly reduce the risk of HIV infection. This proof of concept, announced in July 2010, focused attention on the need to confirm the safety and effectiveness of this product, obtain regulatory approval from the relevant national authorities, and prepare for introduction of this new HIV prevention technology designed to help meet the needs of women in developing countries. Simultaneously, other promising microbicide leads are moving forward in the product development pipeline as well. Although research and development (R&D) for improved and alternative microbicide products will continue to be of interest, a new and broader range of activities is now needed to move the USAID program forward toward microbicide introduction.
This APS is intended to support the creative research and other innovative activities that are now essential to advance potential microbicides toward regulatory approval and then to successfully introduce them into delivery programs. Attaining these objectives will fill a critical gap in the options women and girls currently have to protect themselves from HIV infection. |
| Expected Number of Awards: | – |
| Assistance Listings: | 98.001 — USAID Foreign Assistance for Programs Overseas |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | Jun 06, 2014 |
| Last Updated Date: | Jul 03, 2014 |
| Original Closing Date for Applications: | Jul 09, 2014 |
| Current Closing Date for Applications: | Jul 11, 2014 |
| Archive Date: | Aug 08, 2014 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $4,000,000 |
| Award Floor: | $1,000,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility requirements included in attached document. |
Additional Information
| Agency Name: | Agency for International Development |
| Description: | Description of funding opportunity included in attached document. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Petrina Williams
Contract Specialist Phone 202-567-5368 Email:pwilliams@usaid.gov |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | APS-OAA-14-000076 |
| Funding Opportunity Title: | Microbicide Research, Development, and Introduction, Round 3 |
| Opportunity Category: | Other |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Other (see text field entitled “Explanation of Other Category of Funding Activity” for clarification) |
| Category Explanation: | The CAPRISA 004 clinical trial of 1% tenofovir gel, conducted by South African investigators and jointly supported by USAID and the Government of South Africa, was the first demonstration that a vaginal microbicide could significantly reduce the risk of HIV infection. This proof of concept, announced in July 2010, focused attention on the need to confirm the safety and effectiveness of this product, obtain regulatory approval from the relevant national authorities, and prepare for introduction of this new HIV prevention technology designed to help meet the needs of women in developing countries. Simultaneously, other promising microbicide leads are moving forward in the product development pipeline as well. Although research and development (R&D) for improved and alternative microbicide products will continue to be of interest, a new and broader range of activities is now needed to move the USAID program forward toward microbicide introduction.
This APS is intended to support the creative research and other innovative activities that are now essential to advance potential microbicides toward regulatory approval and then to successfully introduce them into delivery programs. Attaining these objectives will fill a critical gap in the options women and girls currently have to protect themselves from HIV infection. |
| Expected Number of Awards: | – |
| Assistance Listings: | 98.001 — USAID Foreign Assistance for Programs Overseas |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 03, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Jul 09, 2014 |
| Archive Date: | Aug 08, 2014 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $4,000,000 |
| Award Floor: | $1,000,000 |
Eligibility
| Eligible Applicants: | Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Eligibility requirements included in attached document. |
Additional Information
| Agency Name: | Agency for International Development |
| Description: | Description of funding opportunity included in attached document. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Petrina Williams
Contract Specialist Phone 202-567-5368 Email:pwilliams@usaid.gov |
Related Documents
Folder 256908 Full Announcement-1 -> Microbicides APS-OAA-14-000076.pdf
Folder 256908 Revised Full Announcement-1 -> APS-OAA-14-000076 Amendment 1.pdf
Folder 256908 Other Supporting Documents-Amendment #2 1 -> APS-OAA-14-000076 Amendment 2.pdf
Packages
| Agency Contact Information: | Petrina Williams Contract Specialist Phone 202-567-5368 Email: pwilliams@usaid.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 98.001 | PKG00198745 | Jul 11, 2014 | View |
Package 1
Mandatory forms
256908 SF424_2_1-2.1.pdf
256908 Other-1.1.pdf
256908 SF424B-1.1.pdf
256908 SF424A-1.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
